Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study

Journal of Clinical Pharmacology

Volumn 52, Issue 3, 2012, Pages 306-318

  Nagase, Shinichi ^a   Ohyama, Michiyo ^a   Hashimoto, Yoshitaka ^a   Small, Maria ^a   Kuwayama, Tomohiro ^a   Deacon, Steve ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

biochemical markers of bone turnover; Cathepsin K inhibitor; ONO 5334; osteoporosis; pharmacodynamics; phase 1

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; ONO 5334; OSTEOCALCIN; PLACEBO; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BONE TURNOVER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EVENING DOSAGE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE DISCOMFORT; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; OSTEOCLAST; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN MANIFESTATION; SUBCUTANEOUS TISSUE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

AREA UNDER CURVE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; THIAZOLIDINES;

EID: 84860131057     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011399080     Document Type: Article

References (21)

1. Berti PJ, Storer AC. Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol. 1995 ; 246: 273-283
2. Nishi Y, Atley L, Eyre DE, et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res. 1999 ; 14: 1902-1908
3. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996 ; 273: 1236-1238
4. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998 ; 95: 13453-13458
5. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res. 1999 ; 14: 1654-1663
6. Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. Paper presented at: American Society for Bone and Mineral Research 2006 ; Philadelphia, PA ;..
7. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010 ; 25: 937-47
8. Ono Pharmaceutical Co., Ltd ;
9. Ono Pharmaceutical Co., Ltd ;
10. Ono Pharmaceutical Co., Ltd ;
11. Yamada H, Mori H, Nakanishi Y, et al. Orally active cathepsin K inhibitor, ONO-5334, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys. Paper presented at: American Society for Bone and Mineral Research 2009 ; Denver, CO ;..
12. Ono Pharmaceutical Co., Ltd ;
13. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies [published online ahead of print May 6, 2009]. Clin Pharmacol Ther. 2009 ; 86: 175-182
14. Reid DM, Hosking D, Kendler D, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS international. Clin Drug Investig. 2006 ; 26: 63-74
15. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 ; 356: 1809-1822
16. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 ; 24: 153-161
17. Pennypacker BL, Duong LT, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits [published online ahead of print August 23, 2010]. J Bone Miner Res. :
18. Yamada H, Mori H, Nakanishi Y, et al. Orally active cathepsin K inhibitor, ONO-5334, potently improved bone mineral density not only in trabecular bone but also in cortical bone in ovariectomized cynomolgus monkeys. Paper presented at: American Society for Bone and Mineral Research 2009 Annual Meeting ; Denver, CO ;..
19. Tanaka M, Yamada H, Mori H, et al. Efficacy of ONO-5334, a cathepsin K inhibitor, on bone geometry and histomorphometry in cortical bone in ovariectomized cynomolgus monkeys. Paper presented at: American Society for Bone and Mineral Research 2010 Annual Meeting ; Toronto, OT, Canada ;..
20. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007 ; 89: 349-353
21. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy [published online ahead of print December 14, 2004]. J Clin Endocrinol Metab. 2005 ; 90: 1294-1301